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Abstract The insulin-like growth factor-I receptor (IGF-IR)
plays a critical role in breast tumorigenesis and is overexpressed
in most primary tumors. BRCA1 is a transcription factor in-
volved in numerous cellular processes, including DNA damage
repair, cell growth, and apoptosis. Consistent with its tumor
suppressor role, we demonstrated that BRCA1 repressed the
activity of co-transfected IGF-IR promoter reporter constructs
in a number of breast cancer-derived cell lines. Results of elec-
trophoretic mobility shift assay showed that BRCA1 did not
exhibit any speci¢c binding to the IGF-IR promoter, although
it prevented binding of Sp1. Co-immunoprecipitation experi-
ments demonstrated that BRCA1 action was associated with
speci¢c interaction with Sp1 protein. Furthermore, using a se-
ries of glutathione S-transferase-tagged BRCA1 fragments, we
mapped the Sp1-binding domain to a segment located between
aa 260 and 802. In summary, our data suggest that the IGF-IR
gene is a novel downstream target for BRCA1 action.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The insulin-like growth factor-I receptor (IGF-IR) mediates
the mitogenic, antiapoptotic, and transforming e¡ects of the
IGF ligands, IGF-I and IGF-II [1,2]. The IGF axis has a
central role in cell cycle progression, as demonstrated by the
fact that receptor overexpression in ¢broblasts abrogates all
requirements for additional growth factors [3]. IGFs, acting
through the IGF-IR, have an important role in normal mam-
mary gland growth and morphogenesis, as well as in mam-
mary tumorigenesis [4,5]. Furthermore, epidemiological data
demonstrated a positive correlation between circulating IGF-I
concentration and risk of breast cancer [6]. The relative risk of
developing breast cancer in premenopausal women less than
50 years of age was 4.6-fold higher in individuals in the upper
tertile of IGF-I values (compared to women in the lower
tertile). These studies, thus, suggest that ligand-dependent ac-
tivation of the IGF-IR by endocrine IGF-I may be a predis-
posing factor in breast cancer etiology.
The level of expression of the IGF-IR gene during normal
development, as well as in pathological states, is determined,
to a large extent, at the transcriptional level. The IGF-IR
promoter is extremely G-C-rich and contains multiple binding
sites for transcription factor Sp1, a zinc-¢nger protein that
strongly stimulates IGF-IR gene expression [7]. In addition,
transcription of the IGF-IR gene is negatively regulated by a
number of tumor suppressors, including p53 and the Wilms’
tumor protein, WT1 [8,9].
The BRCA1 gene encodes a 220-kDa phosphorylated tran-
scription factor whose mutation was correlated with the ap-
pearance of breast and ovarian cancer at very young ages [10].
Evidence in support of a tumor suppressor role for BRCA1
was provided by studies showing that transfer of BRCA1
arrested growth of breast and ovarian, but not colon or
lung, cancer cell lines [11]. BRCA1 participates in multiple
biological pathways, including DNA damage repair, cell
growth and apoptosis, and gene transcription [12]. Consistent
with its tumor suppressor role, we have previously shown that
BRCA1 repressed the activity of co-transfected IGF-IR pro-
moter^luciferase reporter constructs in a number of cell lines
[13]. Furthermore, deletion analysis demonstrated that the
promoter region responsible for this e¡ect included a number
of Sp1 sites.
In view of the central role of the IGF-IR in normal mam-
mary gland growth and development, as well as in mammary
tumorigenesis, and to extend our previous observations on
transcriptional regulation of the IGF-IR gene by BRCA1
and Sp1, we have addressed the potential functional and phys-
ical interactions between these important proteins in control-
ling IGF-IR gene expression.
2. Materials and methods
2.1. Cell culture, plasmids, and DNA transfection
The human breast cancer-derived T47D, MCF-7, and MDA-MB-
231, and the osteogenic sarcoma-derived Saos-2 cell lines were main-
tained in Dulbecco’s modi¢ed Eagle’s medium with 10% fetal bovine
serum (FBS), 2 mM glutamine, and 50 Wg/ml gentamicin sulfate. The
BRCA1-null HCC1937 breast cancer cell line was maintained in
RPMI 1640 medium with 10% FBS. HCC1937 cells were provided
by Dr. L.C. Brody (National Center for Human Genome Research,
NIH, Bethesda, MD, USA). Drosophila Schneider cells were grown in
Schneider’s Drosophila medium containing 10% FBS, 2 mM gluta-
mine, and 20 Wg/ml gentamicin sulfate.
For transient co-transfection experiments, a genomic DNA frag-
ment extending from nucleotides 3476 to +640 (nucleotide 1 corre-
sponds to the transcription start site of the rat IGF-IR gene) was
employed [14]. Wild-type and 185delAG mutant BRCA1 expression
vectors (in pcDNA3) [15] were provided by Dr. L.C. Brody.
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T47D and MDA-MB-231 cells were transfected using Lipofectam-
ine-2000 (Life Technologies), HCC1937 cells were transfected using
Fugene-6 (Roche), MCF-7 cells were transfected using jetPEI1 (Poly-
plus), and Schneider cells were transfected with calcium phosphate
(Life Technologies). Cells were harvested 40 h after transfection,
and luciferase and L-galactosidase (L-gal) activities were measured
as previously described [8]. Promoter activities were expressed as lu-
ciferase values normalized for L-gal.
2.2. In vitro transcription and translation reactions
Coupled in vitro transcription/translation of BRCA1 was per-
formed using the TnT0 T7 Quick Coupled Transcription/Translation
System (Promega). T7 RNA polymerase-driven in vitro transcription
reactions were followed by in vitro translations in the presence of
[35S]methionine, or unlabeled methionine for electrophoretic mobility
shift assay (EMSA), using rabbit reticulocyte lysates. In vitro trans-
lation products were electrophoresed through 8% sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS^PAGE) and autoradio-
graphed for 20 h.
2.3. Co-immunoprecipitation studies
Cells were collected and processed as described [16]. Cellular ex-
tracts were immunoprecipitated with antibodies against the C- or
N-terminal domains of BRCA1 (C-20 and D-20 respectively, Santa
Cruz Biotechnology), or with anti-Sp1 (Pep-2). Immunoprecipitates
were electrophoresed through 8% SDS^PAGE, followed by transfer
of the proteins to nitrocellulose membranes. Membranes were blocked
with 3% bovine serum albumin and then incubated with either anti-
Sp1 or anti-BRCA1 (C-terminal) antibodies, washed and incubated
with horseradish peroxidase-conjugated secondary antibody. BRCA1
and Sp1 were detected using the SuperSignal0 West Pico Chemilumi-
nescent Substrate (Pierce).
2.4. EMSA
A double-stranded oligonucleotide with the sequence AGCCCG-
CCCGCCCTGCCGCCGCCC, which corresponds to nt 3380/3357
of the IGF-IR 5P-£anking region and includes two overlapping Sp1
sites (underlined) [7], was used in EMSA. In addition, a DNA frag-
ment extending from nt 340 to +115 (encompassing the IGF-IR
initiator element) was employed. Binding reactions included 1 Wl of
in vitro translated BRCA1 protein and/or 0.375 footprinting units
(f.p.u.) of recombinant Sp1 protein (Promega). EMSA was performed
as previously described [16].
Fig. 1. Functional interactions between BRCA1 and Sp1 in control
of IGF-IR promoter activity. A: Scheme of the IGF-IR promoter^
luciferase construct, p(3476/+640)LUC, used in transient transfec-
tions. The reporter plasmid contains 476 bp of 5P-£anking (open
bar) and 640 bp of 5P-untranslated (closed bar) sequences. The ar-
row denotes the initiator element (INR). Closed triangles represent
GC boxes footprinted by Sp1 [7]. Open triangles are Sp1 sites
(GGGCGG) that did not generate detectable footprints. Bars A and
B denote probes used in EMSA. B: The p(3476/+640)LUC plasmid
(5 Wg) was co-transfected into Schneider cells, together with 300 ng
of an Sp1 expression vector (pPacSp1, or empty pPac0), in the ab-
sence or presence of a BRCA1 vector (1 Wg). Luciferase activity was
measured after 72 h. A value of 1 was given to the activity in the
absence of expression vectors. Results are meanPS.E.M. of four ex-
periments.
Fig. 2. Regulation of IGF-IR promoter activity by BRCA1 in breast cancer-derived cell lines. A: T47D, MDA-MB-231, and HCC1937 cells
were cotransfected with a BRCA1 vector, together with the p(3476/+640)LUC reporter and pCMVL. After 40 h, cells were harvested and the
levels of luciferase and L-gal activities were measured. Luciferase values, normalized for L-gal, are expressed as a percentage of the luciferase
activity of the empty pcDNA3 vector (black columns). Experiments were performed four to six times, each in duplicate. Bars are meanP
S.E.M. B: MCF-7 cells were co-transfected with the p(3476/+640)LUC reporter, along with wild-type or 185delAG mutant BRCA1. The ¢gure
shows the results of a typical experiment, performed in duplicate dishes and repeated six times.
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2.5. GST-a⁄nity puri¢cation and association assays
Six glutathione S-transferase (GST)^BRCA1 fusion proteins (aa
1^324; 260^553; 502^802; 758^1064; 1005^1313; and 1314^1863)
were provided by Dr. D.M. Livingston (Harvard Medical School)
[17]. Recombinant proteins were produced in Escherichia coli using
standard procedures. For GST a⁄nity puri¢cation, bacterial lysates
were incubated with glutathione beads (Pharmacia) for 1 h, after
which beads were washed with phosphate-bu¡ered saline and incuba-
ted for 18 h with whole cell extracts of Schneider cells that were
transfected with 1.5 Wg of an Sp1 expression vector under the control
of an actin promoter, pPacSp1, or empty pPac0. Following incubation,
beads were washed, boiled for 10 min in sample bu¡er, electropho-
resed through 10% SDS^PAGE, transferred to nitrocellulose mem-
branes, and blotted with GST or Sp1 antibodies.
Fig. 3. EMSA analysis of BRCA1^Sp1 interactions at the IGF-IR promoter. A: In vitro transcription/translation reactions were performed
with the TnT0 System using 1 Wg of pcDNA3 or BRCA1 vector. Translation reactions were performed in the presence of [35S]methionine (or
unlabeled methionine for EMSA) using rabbit reticulocyte lysates and electrophoresed through 8% SDS^PAGE. B: A double-stranded oligomer
(nt 3380/3357, probe A in Fig. 1A) was end-labeled with [Q-32P]ATP, and used in binding reactions with 1 Wl of in vitro translated BRCA1
(lane 2) or control pcDNA3 reaction product (lane 1), Sp1 (0.375 f.p.u.) (lane 3), Sp1 and pcDNA3 (lane 4), or Sp1 and BRCA1 (lane 5).
Competition experiments were performed using excess of the unlabeled probe (Sp., speci¢c competitor, lane 5) or a control oligomer lacking
Sp1 site (N.S., non-speci¢c competitor, lane 7). The arrow denotes the position of the DNA^Sp1 complex. C: A labeled promoter fragment
(340/+115, probe B in Fig. 1A) was employed in EMSA with BRCA1 (5 Wl) (lane 2) or control pcDNA3 reaction product (lane 1), Sp1 (0.375
f.p.u.) (lane 3), Sp1 and pcDNA3 (lane 4), or Sp1 and 0.5, 1, or 2 Wl of BRCA1 (lanes 5^7, respectively).
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3. Results
Increased expression of the IGF-IR gene is a typical hall-
mark in breast tumorigenesis [5]. Levels of IGF-IR mRNA
and protein are highly augmented in well and moderately
di¡erentiated carcinomas and decrease at advanced metastatic
stages [18]. Because BRCA1 functions as a tumor suppressor
capable of arresting growth of mammary cells, whereas mu-
tant BRCA1 are unable to halt proliferation, we examined
whether BRCA1 is able to control IGF-IR gene transcription.
In previous studies we showed that BRCA1 suppressed the
activity of co-transfected IGF-IR promoter constructs in Chi-
nese hamster ovary, Saos-2, and MCF-7 cells [13]. Deletion
analysis demonstrated that most of the suppressive e¡ect of
BRCA1 was ascribed to a fragment located between nt 3476
and 3188 in the IGF-IR 5P-£anking region, a region previ-
ously shown to include four speci¢c Sp1 sites (at nt 3399/
3394, 3378/3373, 3374/3369, and 3193/3188) (Fig. 1A)
[7]. To address the potential functional interactions between
BRCA1 and Sp1 in regulation of the IGF-IR gene, co-trans-
fections were performed in Sp1-null Drosophila Schneider cells
using BRCA1 and Sp1 expression vectors, along with the
p(3476/+640)LUC reporter. In these cells, Sp1 induced a
V175-fold stimulation of the IGF-IR promoter, while
BRCA1 suppressed 45% of the Sp1-induced transactivation
(Fig. 1B). These results replicate our previous data [13].
To examine the transcriptional e¡ect of BRCA1 in di¡erent
breast cancer-derived cell lines, we analyzed the T47D, MDA-
MB-231, and HCC1937 cells. For this purpose, cells were co-
transfected with a BRCA1 vector, along with the p(3476/
+640)LUC reporter and a L-gal vector (pCMVL). As shown
in Fig. 2A, expression of BRCA1 suppressed promoter activ-
ity byV42^45%. On the other hand, co-transfection of MCF-
7 cells with a vector encoding a truncated BRCA1 mutant
(185delAG) had a reduced e¡ect (Fig. 2B).
To assess whether the transcriptional activity of BRCA1
was associated with speci¢c binding to the IGF-IR promoter,
EMSA was performed using in vitro translated BRCA1 (Fig.
3A). The V220-kDa protein was employed in binding assays
using an oligomer comprising nt 3380/3357 of the IGF-IR
promoter. This fragment is included in the region shown to
mediate the BRCA1 response, and contains two overlapping
Sp1 elements. As shown in Fig. 3B, lane 2, BRCA1 did not
display any noticeable binding, whereas incubation of the
DNA fragment with recombinant Sp1 generated one retarded
band (lane 3). Band formation was abrogated when reactions
were performed in the presence of aV40-fold molar excess of
unlabeled probe (lane 6), but not when a control oligomer
lacking Sp1 sites (nt 3305/3325) was employed (lane 7). Ad-
dition of BRCA1 protein (lane 5), but not empty pcDNA3
translation product (lane 4), prevented the formation of the
Sp1^IGF-IR promoter complex.
EMSA was also performed using a genomic DNA fragment
(nt 340/+115) that includes the initiator element. Since the
initiator acts in vivo in concert with a TATA box or upstream
elements (including Sp1) to direct transcription initiation, we
examined whether the e¡ect of BRCA1 was associated with
speci¢c binding to this region. Incubation of the DNA frag-
ment with BRCA1 did not generate any retarded band (Fig.
3C, lane 2). Despite the fact that this region, which contains
V70% G-C nucleotides, lacks canonical Sp1 sites, addition of
Sp1 protein generated a shifted band (lane 3). Addition of
BRCA1 abrogated Sp1^DNA complex formation in a dose-
dependent manner (lanes 5^7).
To investigate whether the ability of BRCA1 to prevent Sp1
binding to the IGF-IR promoter, and to repress Sp1-stimu-
lated promoter activity, was associated with interaction with
Sp1, co-immunoprecipitation experiments were performed.
For this purpose, untransfected Saos-2 and MCF-7 cells,
which express both proteins, were lysed and immunoprecipi-
tated with anti-BRCA1 or anti-Sp1. Precipitates were electro-
phoresed through 8% SDS^PAGE, transferred to nitrocellu-
lose membranes, and blotted with anti-BRCA1 (C-terminal)
(Fig. 4A,B, upper panels) or anti-Sp1 (lower panels). Results
obtained showed that, in both cell lines, immunoblotting with
anti-BRCA1 identi¢ed the 220-kDa protein in anti-Sp1 immu-
noprecipitates. Likewise, immunoblotting with anti-Sp1 iden-
ti¢ed the 95- and 106-kDa bands in anti-BRCA1 precipitates.
Fig. 4. In vivo association of BRCA1 and Sp1. Saos-2 (A) and
MCF-7 (B) cells were lysed and immunoprecipitated with antibodies
against the C- or N-terminal domains of BRCA1 (Saos-2), or anti-
C-terminal BRCA1 (MCF-7), or with anti-Sp1. Precipitates were
separated through 8% SDS^PAGE, blotted, and incubated with
anti-BRCA1 (C-terminal) (upper panels) or anti-Sp1 (lower panels).
The positions of the V220-kDa BRCA1 and 95- and 106-kDa Sp1
proteins are denoted by the arrows.
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No BRCA1 or Sp1 was detected in control samples precipi-
tated with preimmune rabbit serum (not shown).
To identify the BRCA1 domain(s) involved in Sp1 interac-
tion, six GST^BRCA1 fusion proteins spanning the entire
sequence were generated in E. coli (Fig. 5A). GST^BRCA1
proteins were bound to glutathione Sepharose beads and in-
cubated with lysates from Schneider cells that were transfected
with an Sp1 vector (pPacSp1), or control cells transfected with
empty pPac0. Bound proteins were released, separated through
SDS^PAGE, and immunoblotted with Sp1 and GST antibod-
ies. Results obtained showed that partially overlapping GST^
BRCA1 fragments 2 (aa 260^553) and 3 (aa 502^802) exhib-
ited the highest a⁄nity to Sp1 (Fig. 5B). Fragment 4 (aa 785^
1064) bound Sp1 with reduced a⁄nity. No binding was seen
when lysates from cells transfected with empty pPac0 were
employed (lower panel).
4. Discussion
The IGFs have been recognized as major regulators of
mammary epithelial cell and breast cancer cell growth [19].
The IGF-IR, which mediates the mitogenic actions of the
IGFs, has been identi¢ed as a central player in breast carcino-
genesis [5,20]. Increased expression of the IGF-IR gene has
been associated with radioresistance and tumor recurrence, as
well as with development of resistance to chemotherapeutic
agents [21,22]. Consistent with the tumor suppressor role of
BRCA1, we showed that the IGF-IR promoter is repressed by
BRCA1, and that the regulatory region responsible for this
e¡ect includes a cluster of Sp1 sites [13]. Furthermore, coex-
pression experiments demonstrated that BRCA1 repressed the
Sp1-induced transactivation of the IGF-IR gene, suggesting
that the mechanism of action of BRCA1 involves potential
interaction(s) with Sp1. In the present study we investigated
the physical association between BRCA1 and Sp1 in tran-
scriptional regulation of the IGF-IR gene.
To explore whether the transcriptional activity of BRCA1
was associated with DNA binding to speci¢c IGF-IR pro-
moter regions, EMSA experiments were performed using
full-length in vitro translated BRCA1. Results of EMSA per-
formed under a variety of experimental conditions showed
that BRCA1 did not display any substantial binding activity
towards probes encompassing Sp1 sites and the initiator ele-
ment. These results suggest that the e¡ect of BRCA1 involves,
most probably, protein^protein associations with additional
DNA binding transcription factors. A recent paper has dem-
onstrated that recombinant BRCA1 binds strongly to DNA,
although without sequence speci¢city [23]. BRCA1 showed a
preference for branched DNA structures and generated pro-
tein^DNA complexes that included multiple DNA molecules.
Fig. 5. Identi¢cation of the Sp1-binding region of BRCA1. A: Six GST^BRCA1 fusion proteins were generated in E. coli. The ¢gure shows a
Coomassie blue-stained gel. M, molecular weight markers. B: Equal amounts of GST^BRCA1 fusion proteins (and control GST) were bound
to glutathione beads, after which they were incubated with extracts of Sp1-transfected Schneider cells (upper panel), or control cells (lower pan-
el). Bound proteins were recovered, electrophoresed, and immunoblotted with anti-Sp1. C, control samples consisting of Sp1-transfected cells
immunoprecipitated with anti-Sp1 and immunoblotted for Sp1.
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Furthermore, we cannot discard the possibility that lack of
DNA-binding activity of the in vitro translated BRCA1 re-
sulted from its lower speci¢c activity in comparison to the
E. coli-expressed BRCA1 used by Paull et al. [23].
In previous studies we showed that the IGF-IR promoter is
highly responsive to Sp1 and that transcriptional control by
Sp1 occurs primarily through a cluster of four GC boxes in
the 5P-£anking region [7]. The results of the present study are
consistent with a model in which physical association between
BRCA1 and Sp1 prevents Sp1 binding to high-a⁄nity sites in
the IGF-IR promoter, with ensuing reduction in promoter
activity. BRCA1 domains involved in Sp1 binding include
the exon 11-encoded sequence. Interestingly, the same domain
was recently shown to bind STAT1 following interferon-Q
stimulation [24]. Mechanisms of action involving interactions
with, and sequestering of, Sp1 were reported for other tumor
suppressors, including Rb [25] and VHL [26]. Furthermore,
estrogen receptor K suppressed IGF-IR promoter activity in
aortic smooth muscle cells via a mechanism that involves in-
hibition of Sp1 binding to the promoter [27].
However, suppression of the IGF-IR promoter is not lim-
ited to BRCA1. We have previously demonstrated that tumor
suppressor WT1 binds both upstream and downstream of the
IGF-IR gene transcription start site and suppresses promoter
activity in functional assays [14]. Likewise, p53 suppressed
promoter activity via a mechanism that involves interaction
with the TATA box-binding protein [8]. Taken together, these
studies suggest that the IGF-IR gene constitutes a common
downstream target to various families of tumor suppressors.
Inhibitory control of the IGF-IR gene, with ensuing reduction
in the levels of cell surface IGF binding sites, has been postu-
lated to keep the receptor in its ‘non-mitogenic’ mode, thus
preventing from the cell to engage in any type of mitogenic
activity [28]. The moderate inhibitory activity of BRCA1
(V42^45% inhibition) compared to that of WT1 (V82^
87%) [9] and p53 (V85^90%) [8] probably re£ects its moder-
ate e⁄cacy as a growth suppressor in comparison to other
tumor suppressors.
In conclusion, we have presented evidence that transcrip-
tion of the IGF-IR gene in breast cancer-derived cell lines is
under the inhibitory control of BRCA1. The mechanism of
action of BRCA1 involves speci¢c binding to Sp1, thus pre-
venting from this zinc-¢nger protein from binding to, and
transactivating, the IGF-IR promoter. Loss of BRCA1 func-
tion in familial and sporadic breast cancer may result in con-
stitutive gene activation by Sp1, with ensuing increases in
IGF-IR mRNA and binding, and enhanced activation of
cell surface receptors by locally produced and/or circulating
IGFs.
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